Dendrimer-like porous hybrid particles for cancer immunotherapy
발표자
()
초록
내용
Cancer treatments have improved since the development of cancer immunotherapy using immune checkpoint inhibitors (ICIs). However, limitations on clinical usefulness such as low delivery rates to target sites still existed. Here, we prepared Dendrimer-like porous silica nanoparticles called DPSNs through a one-pot sol-gel reaction to overcome the previous ICI-based immunotherapeutic strategies. The DPSNs revealed strong stability even after long-term storage and have a larger surface area than spherical particles of the same size. To conjugate ICIs to the surface of DPSNs, epoxy silane was modified using (3-Glycidyloxypropyl)trimethoxysilane (GPTMS). As a result, ICI-conjugated DPSNs were able to increase the immune response and showed a dramatic anticancer efficacy. Thus, DPSN, combined with the functionalization of various immuno-enhancing agents, can potentially be applied to next-generation cancer immunotherapy drugs.